EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Progress in RNA‐Targeted Therapeutics for Human Diseases

Wangzheqi Zhang, Aimin Jiang, Bin-Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang iD

MedComm · 2026-02 · 7 (2)

DOI: 10.1002/mco2.70607 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 05.02.2026. Verfasst von Wangzheqi Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Changzheng Hospital, Naval Medical University (Second Military Medical University) Shanghai China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 309 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA‐targeted therapy is reshaping molecular medicine by shifting the traditional “protein‐centric” view toward an “RNA‐regulatory network” paradigm. Beyond carrying genetic information, RNA plays essential roles in posttranscriptional regulation, signaling pathways, and epigenetic modulation. Advances in high‐throughput sequencing, structural biology, and delivery technologies have accelerated the development of diverse RNA therapeutics, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNA) modulators, messenger RNA (mRNA) therapeutics, aptamers, short hairpin RNA, and CRISPR/Cas‐guided single‐guide RNAs. However, a concise comparison of these major RNA modalities and the translational barriers that limit their broader clinical application is still lacking. This review outlines the mechanisms and representative applications of these RNA‐based strategies in gene silencing, editing, protein replacement, immune activation, and targeted drug delivery. Special emphasis is placed on ASOs and siRNAs for neurological, metabolic, and infectious diseases, as well as mRNA therapeutics that are transforming vaccine development. Common challenges‐such as in vivo stability, delivery efficiency, and immune activation‐are also discussed. Finally, we highlight how chemical modification, nanotechnology, and artificial intelligence‐assisted design are enhancing the specificity, stability, and safety of RNA therapeutics, providing a framework for advancing next‐generation precision RNA medicine.

Schlagwörter

Stichwörter der Autor:innen

CRISPR/Cas9RNA‐targeted therapyantisense oligonucleotidesmessenger RNAsmall interfering RNA

Autor:innen und Institutionen

  • Department of Urology Changzheng Hospital, Naval Medical University (Second Military Medical University) Shanghai China.
  • Faculty of Anesthesiology Changhai Hospital, Naval Medical University (Second Military Medical University) Shanghai China.
  • Department of Urology No. 905 Hospital of PLA Navy, Naval Medical University (Second Military Medical University) Shanghai China.
  • Department of Urology Changhai Hospital, Naval Medical University (Second Military Medical University) Shanghai China.
  • Department of Urology The First Naval Hospital of Southern Theater Command Zhanjiang China.
  • Clinical College of Traditional Chinese Medicine Gansu University of Chinese Medicine, Gansu University of Chinese Medicine Lanzhou Gansu Province China.

ORCID-Profile: Linhui Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Jiang, A., Jia, B. K., Jin, Y., Chen, Y., Li, Z., Liao, Y., Zhang, H., Lin, Z., Fang, X., & Wang, L. (2026). Progress in RNA‐Targeted Therapeutics for Human Diseases. MedComm, 7(2). https://doi.org/10.1002/mco2.70607

Vancouver

Zhang W, Jiang A, Jia BK, Jin Y, Chen Y, Li Z, et al. Progress in RNA‐Targeted Therapeutics for Human Diseases. MedComm. 2026;7(2). doi:10.1002/mco2.70607

BibTeX
@article{Zhang2026,
  author = {Zhang, Wangzheqi and Jiang, Aimin and Jia, Bin-Kui and Jin, Yuming and Chen, Yinghu and Li, Zhaoyu and Liao, Yan and Zhang, Haoling and Lin, Zhiheng and Fang, Xiao and Wang, Linhui},
  title = {Progress in RNA‐Targeted Therapeutics for Human Diseases},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.1002/mco2.70607}
}
Kostenlos starten →